Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Cardiology

Hospital Treatment and Interventions

At a Glance

Hospital treatment for a heart attack depends on whether it is a STEMI, NSTEMI, or Type 2 MI. Doctors may restore blood flow with angioplasty and a stent, dissolve a clot with medication, or treat the underlying stress causing the heart injury.

When you arrive at the hospital with a heart attack, the medical team’s primary goal is to stabilize you, identify the cause, and typically restore blood flow to your heart muscle as quickly as possible. The specific interventions you receive depend heavily on the type of heart attack you are having and the resources available at the hospital.

The Emergency Response: STEMI Treatment

If your electrocardiogram (ECG) shows a STEMI (ST-Elevation Myocardial Infarction), you are in a time-critical emergency. This usually means a major artery requires immediate attention to save heart muscle.

  • Primary PCI (Angioplasty): This is the preferred treatment if it can be performed within 120 minutes of your first medical contact, depending on the system’s guidelines [1][2]. A doctor threads a thin tube (catheter) to the blockage and uses a small balloon to open the artery. They usually place a stent—a tiny mesh tube—to keep the vessel open. Modern drug-eluting stents (DES), which slowly release medicine to prevent the artery from scarring shut again, are the standard of care [3].
  • Fibrinolysis (“Clot-Busters”): If the hospital does not have a specialized catheterization lab, and you cannot be transferred to one within the designated time window (e.g., 120 minutes), doctors may use powerful medications called fibrinolytics to dissolve the clot [4][2]. This is only considered in appropriate patients without major contraindications, such as a history of intracranial bleeding. This is typically followed by a planned transfer to a larger hospital for a follow-up angiogram (often within 2-24 hours), or immediate rescue PCI if the medication fails to restore blood flow [5].

The Strategic Response: NSTEMI Treatment

If you have an NSTEMI (Non-ST-Elevation Myocardial Infarction), the situation remains an emergency, but the timeline is driven by clinical risk [6].

  • Immediate and Early Invasive Strategies: Very-high-risk patients (experiencing shock, malignant arrhythmias, or ongoing refractory ischemia) may require immediate angiography. For other high-risk patients, most benefit from an angiogram within 24 hours of arriving [7][8], while lower-risk patients can be managed later.
  • Medical Stabilization: You will likely receive antiplatelet drugs and anticoagulants to stabilize the plaque and prevent new clots from forming while you wait for your procedure [9][10].

Type 2 MI: Treating the Trigger

A Type 2 Myocardial Infarction is handled differently because it isn’t caused primarily by a sudden blood clot in a heart artery. Instead, it happens because of a “supply-demand mismatch”—your heart needed more oxygen than it was getting due to another medical stress [11][12]. While a patient might also have underlying fixed obstructive coronary disease, the acute trigger needs attention.

  • Focus on the Cause: Doctors focus on fixing the underlying problem. This might mean treating a severe infection (sepsis), correcting severe anemia (low blood count) with a transfusion, or slowing down a dangerously fast heart rate [13][14].
  • Individualized Care: Clinicians decide separately whether coronary evaluation, antithrombotic therapy, or revascularization is appropriate after treating the primary trigger. Aggressive treatments may not be helpful and could even be harmful without individualized assessment [15][16].

Interventions and Medications

During your procedure, the team uses several tools and medicines to ensure the best outcome:

  • Anticoagulants: You will receive intravenous medications like heparin or bivalirudin to prevent blood from clotting on the wires and stents during the procedure [17][18]. These are distinct from the oral antiplatelet pills you take at home.
  • Thrombectomy: In some cases, a doctor may use a device to manually suction out a large clot (thrombectomy). While this isn’t done for everyone, it can be a vital tool if a large amount of clot is visible [19][20].
  • Microvascular Healing: It is important to know that while a stent can open a large artery instantly, the tiny “micro” vessels downstream and the heart muscle itself need time to heal. Restoring the main flow is just the first step in the recovery process [21].

Post-Procedure Watch: After a catheterization, monitor your access site (wrist or groin). Follow your specific discharge instructions regarding lifting restrictions, and seek urgent help if you notice rapid swelling, severe pain, or bleeding that does not stop with pressure.

Common questions in this guide

How does treatment differ between a STEMI and an NSTEMI?
A STEMI is a time-critical heart attack that usually requires rapid restoration of blood flow, often with angioplasty and a stent. NSTEMI treatment is also urgent, but the timing of angiography and other procedures is based on your clinical risk, with the highest-risk patients treated most quickly.
When is angioplasty and a stent used for a heart attack?
For a STEMI, primary angioplasty, also called PCI, is generally preferred when it can be performed within the recommended time window, often within 120 minutes of first medical contact. A catheter is used to open the blocked artery, and a stent is usually placed to help keep it open.
What happens if a hospital cannot perform angioplasty quickly?
If timely PCI is not available and you are an appropriate candidate, doctors may give a clot-dissolving medicine called a fibrinolytic. You will typically be transferred for an angiogram and may need a planned PCI or an emergency rescue procedure if blood flow is not restored.
How is a Type 2 heart attack treated?
Type 2 myocardial infarction results from an imbalance between the heart’s oxygen supply and demand rather than primarily from a sudden clot. Treatment focuses first on the trigger, such as sepsis, severe anemia, or a dangerously fast heart rate, while decisions about coronary testing and blood-thinning treatment are individualized.
Why are antiplatelet drugs and anticoagulants used during heart attack treatment?
Antiplatelet drugs help stop blood cells from clumping together and forming new clots. Anticoagulants such as heparin or bivalirudin reduce clotting during procedures, including around catheters and stents; your team weighs their benefits against bleeding risk.
What warning signs should I watch for after catheterization?
Check the wrist or groin access site for rapid swelling, severe pain, or bleeding that does not stop with pressure. Seek urgent medical help if any of these problems occur or if they worsen after you leave the hospital.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Was my heart attack classified as a STEMI or an NSTEMI, and how did that classification determine the timing of my procedure?
  2. 2.If a stent was placed, is it a drug-eluting stent, and what size is it?
  3. 3.For my Type 2 heart attack, what was the primary trigger (like anemia or a fast heart rate), and how are we treating that underlying cause?
  4. 4.What anticoagulants were used during my procedure, and what is my specific risk for bleeding versus future clots?
  5. 5.If I received 'clot-busting' medication (fibrinolysis), why was that chosen over an immediate procedure, and what are the next steps for my care?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-segment elevation myocardial infarction: the FAST-MI programme.

    Danchin N, Popovic B, Puymirat E, et al.

    European heart journal 2020; (41(7)):858-866 doi:10.1093/eurheartj/ehz665.

    PMID: 31539043
  2. 2

    Rural and Remote Acute STEMI Diagnosis and Management: Current Status and Future Directions.

    Gadeley R, Arnold R, Amos D, et al.

    Heart, lung & circulation 2025; (34(12)):1332-1343 doi:10.1016/j.hlc.2025.06.1035.

    PMID: 40897570
  3. 3

    [Acute coronary syndrome with ST-elevation].

    Haude M, Rupprecht HJ, Schuster S, Uebis R

    Herz 2019; (44(1)):16-21 doi:10.1007/s00059-018-4775-2.

    PMID: 30627740
  4. 4

    Acute myocardial infarction and ischaemic stroke: differences and similarities in reperfusion therapies-a review.

    Scheldeman L, Sinnaeve P, Albers GW, et al.

    European heart journal 2024; (45(30)):2735-2747 doi:10.1093/eurheartj/ehae371.

    PMID: 38941344
  5. 5

    Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction: A Propensity Score-Matched Analysis.

    Sim DS, Jeong MH, Ahn Y, et al.

    Circulation. Cardiovascular interventions 2016; (9(9)).

    PMID: 27582112
  6. 6

    [Management of acute coronary syndrome : ESC guidelines 2023].

    Buske M, Feistritzer HJ, Jobs A, Thiele H

    Herz 2024; (49(1)):5-14 doi:10.1007/s00059-023-05222-1.

    PMID: 38032511
  7. 7

    European practice patterns for antiplatelet management in NSTE-ACS patients: Results from the REal-world ADoption survey focus on Acute antiPlatelet Treatment (READAPT) survey.

    Angiolillo DJ, Erlinge D, Ferreiro JL, et al.

    International journal of cardiology 2023; (386()):8-16 doi:10.1016/j.ijcard.2023.05.025.

    PMID: 37201617
  8. 8

    Importance of Risk Assessment in Timing of Invasive Coronary Evaluation and Treatment of Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome: Insights From the VERDICT Trial.

    Butt JH, Kofoed KF, Kelbæk H, et al.

    Journal of the American Heart Association 2021; (10(19)):e022333 doi:10.1161/JAHA.121.022333.

    PMID: 34585591
  9. 9

    Antithrombotic PreTreatment and Invasive Strategies in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome.

    Camaro C, Damman P

    Journal of clinical medicine 2020; (9(8)) doi:10.3390/jcm9082578.

    PMID: 32784868
  10. 10

    Clinical Decision Pathway for the Use of Fondaparinux in the Management of Acute Coronary Syndrome (ACS) in Hospitals with and Without Catheter Laboratories: An Expert Opinion from India.

    Ray S, Shivdasani B, Mohan JC, et al.

    Cardiology and therapy 2023; (12(2)):261-274 doi:10.1007/s40119-023-00312-x.

    PMID: 37043080
  11. 11

    Type 2 Myocardial Infarction: JACC Review Topic of the Week.

    Sandoval Y, Jaffe AS

    Journal of the American College of Cardiology 2019; (73(14)):1846-1860 doi:10.1016/j.jacc.2019.02.018.

    PMID: 30975302
  12. 12

    Assessment and Treatment of Patients With Type 2 Myocardial Infarction and Acute Nonischemic Myocardial Injury.

    DeFilippis AP, Chapman AR, Mills NL, et al.

    Circulation 2019; (140(20)):1661-1678 doi:10.1161/CIRCULATIONAHA.119.040631.

    PMID: 31416350
  13. 13

    Assessment of Oxygen Supply-Demand Imbalance and Outcomes Among Patients With Type 2 Myocardial Infarction: A Secondary Analysis of the High-STEACS Cluster Randomized Clinical Trial.

    Bularga A, Taggart C, Mendusic F, et al.

    JAMA network open 2022; (5(7)):e2220162 doi:10.1001/jamanetworkopen.2022.20162.

    PMID: 35816305
  14. 14

    Type 2 myocardial infarction in general medical wards: Clinical features, treatment, and prognosis in comparison with type 1 myocardial infarction.

    Furie N, Israel A, Gilad L, et al.

    Medicine 2019; (98(41)):e17404 doi:10.1097/MD.0000000000017404.

    PMID: 31593092
  15. 15

    Implications of a new clinical classification of acute myocardial infarction.

    Boeddinghaus J, Bularga A, Taggart C, et al.

    European heart journal. Acute cardiovascular care 2025; (14(3)):131-141 doi:10.1093/ehjacc/zuaf002.

    PMID: 39824208
  16. 16

    Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy.

    Reid C, Alturki A, Yan A, et al.

    CJC open 2020; (2(3)):118-128 doi:10.1016/j.cjco.2020.02.005.

    PMID: 32462125
  17. 17

    Anticoagulation in coronary intervention.

    Zeymer U, Rao SV, Montalescot G

    European heart journal 2016; (37(45)):3376-3385 doi:10.1093/eurheartj/ehw061.

    PMID: 26946415
  18. 18

    Factors Affecting Bleeding and Stent Thrombosis in Clinical Trials Comparing Bivalirudin With Heparin During Percutaneous Coronary Intervention.

    Bittl JA, He Y, Lang CD, Dangas GD

    Circulation. Cardiovascular interventions 2015; (8(12)):e002789.

    PMID: 26643738
  19. 19

    Randomized trial of primary PCI with or without routine manual thrombectomy.

    Jolly SS, Cairns JA, Yusuf S, et al.

    The New England journal of medicine 2015; (372(15)):1389-98 doi:10.1056/NEJMoa1415098.

    PMID: 25853743
  20. 20

    Is Atherothromboaspiration a Possible Solution for the Prevention of No-Reflow Phenomenon in Acute Coronary Syndromes? Single Centre Experience and Review of the Literature.

    Manolis AS

    Current vascular pharmacology 2019; (17(2)):164-179 doi:10.2174/1570161116666180101150956.

    PMID: 29298651
  21. 21

    Repetitive catamenial myocardial infarction due to coronary artery spasm: a case report.

    Talmor N, Gurin M, Smilowitz N, et al.

    European heart journal. Case reports 2023; (7(2)):ytad019 doi:10.1093/ehjcr/ytad019.

    PMID: 36793935

This page explains hospital treatment for myocardial infarction for educational purposes only and does not replace medical advice. Your emergency and cardiology teams must guide decisions about procedures, medicines, bleeding risk, and recovery.

Get notified when new evidence is published on myocardial infarction.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.